Featured News See All October 21, 2024 REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 September 17, 2024 REGENXBIO Appoints Mitchell Chan as Chief Financial Officer September 3, 2024 REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect Year All202420232022202120202019201820172016201520142013201220112009 Mar 11, 2024 REGENXBIO to Participate in Upcoming Investor Conferences Mar 06, 2024 REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants Mar 06, 2024 REGENXBIO Announces Proposed Public Offering of Common Stock Mar 05, 2024 REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL Feb 29, 2024 REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial Feb 27, 2024 REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights Feb 21, 2024 REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
Mar 06, 2024 REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
Feb 29, 2024 REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial
Feb 27, 2024 REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
Feb 21, 2024 REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights